Arctic Bioscience AS ABS.OL · NOK

Its shares trade on Oslo Børs under the ticker ABS.OL. It has been listed since 24 February 2021. In the fiscal year to 31 December 2025, it reported revenue of NOK 40.1m and a net loss of NOK 41.0m. At that date it held total assets of NOK 284.7m and shareholders' equity of NOK 173.5m.

Arctic Bioscience AS engages in the development, manufacturing, and marketing of marine ingredients extracted from herring roe. The company is headquartered in Orsta, More Og Romsdal. The company went IPO on 2021-02-24. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The firm is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The firm's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.

Figures and description from our data supplier, not checked against the company's own report.

• Harald NordalChairman of the Board
• Mr. Christer ValderhaugChief Executive Officer
• Mr. Jone SlinningChief Financial Officer
• Per SaeboChief Operating Officer
• Daniele MancinelliChief Technology Officer
• Anders BlindheimChief Marketing Officer
• Mr. Hu CaoDirector
• Mr. Per EggesboDirector
• Ms. Marita HolstadDirector
• Mr. Asbjorn SolvagseideDirector
• Mr. Tore TonsethDirector
• Mr. Jan VartdalDirector

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.